Elevance Health stock: October 21 results set. USD 460 target for Elevance Health stock

Published on 10/20/2026 at 16:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 49.83 billion in the second quarter. Elevance Health stock costs EUR 386.65 on October 20, 2026, up 0.89 percent versus Xetra close.

Reporting date October 21, 2026

Elevance Health will release third-quarter results on October 21, 2026.
Second-quarter revenue reached USD 49.83 billion.
Elevance Health stock costs EUR 386.65 at Lang & Schwarz on October 20, 2026, 0.89 percent above the Xetra close of October 19, 2026.
The price-to-earnings ratio is 19.33 and market capitalization is USD 94.6 billion.

Modernes Krankenhaus-Campus mit Glasfassade und Patienten im Eingangsbereich — Elevance Health Krankenversicherungs-Campus US2855211023 zeigt modernen Gebäudeeingang mit weitläufiger Grünanlage unter blauem Himmel, Illustration mit AI erstellt.

Elevance Health (ISIN US0367521038) will release its third-quarter 2026 financial results on October 21, 2026, before the US market opens, according to Elevance Health. On October 12, Guggenheim raised its target from USD 455.00 to USD 460.00 and maintained a Buy rating, as Investing.com reported. At Lang & Schwarz, the stock was trading at EUR 386.65 on October 20, 2026 at 4:30 p.m. CEST, 0.89 percent above the Xetra close of October 19, 2026 at EUR 383.25.

Revenue sets the next test

Elevance Health reported revenue of USD 49.83 billion for the second quarter of 2026. That was 0.80 percent higher than the year-earlier period, while quarterly earnings per share reached USD 7.45 against a consensus estimate of USD 6.21, according to MarketBeat. The figures give the October 21 release a clear operating benchmark, especially after Guggenheim linked its target increase to improved performance in Medicaid, Medicare Advantage and Individual ACA.

Stock stays below its yearly high

The primary NYSE quote was USD 436.08 at 10:32 a.m. EDT on October 20, 2026. Its USD 274.84 to USD 437.18 52-week range places the stock 0.25 percent below the high, while the company had a market capitalization of USD 94.6 billion and a price-to-earnings ratio of 19.33.

Valuation and reporting date

Guggenheim's USD 460.00 target lies 5.48 percent above the NYSE price of USD 436.08. The company is scheduled to discuss the results and its outlook during an 8:30 a.m. EDT conference call on October 21, 2026, following the 6:00 a.m. EDT release.

Comparison with peers

Elevance Health: up 1.36 percent, price-to-earnings ratio 19.33, market capitalization USD 94.6 billion.
UnitedHealth Group: up 2.38 percent, price-to-earnings ratio 23.76, market capitalization USD 373.9 billion.
Humana: up 2.34 percent, price-to-earnings ratio 40.22, market capitalization USD 51.0 billion.

What the figures leave investors watching

The immediate test is whether third-quarter results support the stronger outlook reflected in the USD 460.00 target. Revenue growth in the second quarter was positive, but the upcoming release will provide the next dated evidence on earnings, medical costs and management guidance.

The EUR 386.65 Lang & Schwarz price on October 20, 2026 at 4:30 p.m. CEST stood 0.89 percent above the Xetra close of October 19, 2026 at EUR 383.25. The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.